Top Page
Sigma Healthcare Ltd
(Sydney:SIG)
Sigma Healthcare Ltd (SIG) vs. iShares MSCI Australia ETF (EWA)
Sigma Healthcare Ltd Business Overview & Revenue Model
Sigma Healthcare Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.84B | 4.89B | 3.32B | 3.66B | 3.45B | 3.40B |
| Gross Profit | 268.60M | 334.05M | 189.82M | 224.07M | 199.42M | 210.61M |
| EBITDA | 41.60M | 55.47M | 53.25M | 50.20M | 30.23M | 68.96M |
| Net Income | -13.84M | -13.84M | 4.51M | 1.81M | -7.24M | 43.53M |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.83B | 1.40B | 1.20B | 1.28B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 14.57M | 14.57M | 356.50M | 16.65M | 31.14M | 16.13M |
| Total Debt | 132.09M | 132.09M | 136.63M | 226.99M | 323.43M | 215.23M |
| Total Liabilities | 991.29M | 991.29M | 531.52M | 723.84M | 786.65M | 705.00M |
| Stockholders Equity | 837.86M | 837.86M | 870.77M | 475.92M | 487.19M | 513.67M |
Cash Flow | ||||||
| Free Cash Flow | -323.50M | -323.50M | 37.25M | 113.34M | -60.48M | -64.56M |
| Operating Cash Flow | -315.59M | -315.59M | 41.97M | 142.74M | -46.28M | -13.13M |
| Investing Cash Flow | -1.60M | -1.60M | 5.73M | -28.60M | -16.59M | 124.36M |
| Financing Cash Flow | -24.73M | -24.73M | 295.82M | -116.94M | 128.89M | -265.71M |
Sigma Healthcare Ltd Technical Analysis
Sigma Healthcare Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | AU$524.72M | 15.63 | 18.59% | 4.90% | 6.73% | 37.16% | |
64 Neutral | AU$10.27B | 19.43 | 6.32% | 5.12% | 9.44% | -0.37% | |
53 Neutral | €35.60B | 61.26 | ― | 0.42% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$2.26B | 45.97 | ― | 2.11% | 14.61% | ― | |
50 Neutral | AU$7.09B | 1,042.23 | 0.38% | 2.59% | 6.82% | -99.27% | |
48 Neutral | €635.37M | -1.21 | -67.21% | ― | -23.02% | 33.11% |
Sigma Healthcare Ltd Corporate Events
Sigma Healthcare Ltd recently held its Annual General Meeting where all proposed resolutions were successfully carried. Key outcomes included the adoption of remuneration reports, re-election of board members, and approval of incentive plans for executives. These decisions reflect the company’s strategic focus on rewarding leadership and ensuring continuity in its governance structure, which may positively impact its operational stability and stakeholder confidence.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.10 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its corporate governance statement for the financial year ending June 30, 2025, which is now available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This disclosure is crucial for stakeholders as it demonstrates Sigma Healthcare’s dedication to maintaining high governance standards, which can impact investor confidence and the company’s industry positioning.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.10 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has released its Corporate Governance Statement for 2025, following its merger with Chemist Warehouse. The statement outlines the updated governance framework for the merged entity, highlighting the company’s commitment to high standards of corporate governance in line with ASX Principles and Recommendations. The Board acknowledges certain challenges post-merger, such as diversity levels and board composition, and plans to address these to align with ASX expectations. The merger has provided unique opportunities and challenges, and the Board is focused on ensuring governance practices meet the needs of the company and its stakeholders.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.10 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd held its Annual General Meeting on October 22, 2025, where key business items were addressed. The meeting included discussions on financial statements, remuneration reports, re-election of directors, and the ratification of the auditor’s appointment. Additionally, two conditional spill resolutions were on the agenda, highlighting the company’s focus on governance and accountability.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.10 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has completed a transformative merger with Chemist Warehouse, marking a pivotal moment in its history. This merger, which has significantly increased Sigma’s market value and placed it among the top 20 companies on the ASX, aims to leverage the strengths of both companies to enhance retail expertise, product offerings, and shareholder value. The merger has already exceeded expectations, with upgraded synergy targets and reduced net debt, providing Sigma with substantial growth potential and improved access to capital markets.
The most recent analyst rating on (AU:SIG) stock is a Hold with a A$3.10 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd, a prominent player in the pharmaceutical industry, has released its annual report for 2025, highlighting a new partnership and various operational insights. The report covers key areas such as logistics, sustainability, and financial performance, indicating a strategic focus on strengthening foundations and future growth. This announcement is significant as it outlines Sigma’s commitment to enhancing its market position and delivering value to stakeholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.40 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has announced its Annual General Meeting (AGM) for 2025, scheduled to be held on October 22, 2025, in a hybrid format. The meeting’s date has been extended due to a recent merger with CW Group Holdings Limited, aligning their financial reporting timelines. Key agenda items include financial reports, remuneration reports, re-election of directors, and approval of incentive plans for the CEO. This AGM is significant as it reflects the company’s strategic alignment post-merger, impacting stakeholders and operational timelines.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.40 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Limited has appointed Richard Murray as its new Chief Financial Officer, effective from October 13, 2025. Murray brings over 30 years of experience in ASX-listed companies, having held senior roles at Total Tools, Premier Investments Ltd, and JB Hi-Fi Limited. His extensive background in financial management and strategic leadership is expected to support Sigma’s growth ambitions both in Australia and globally, as highlighted by CEO Vikesh Ramsunder. Murray expressed enthusiasm about joining Sigma at a pivotal time, aiming to contribute to the company’s ongoing success.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.40 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Limited has announced a new dividend distribution of AUD 0.013 per share for its ordinary fully paid securities. The dividend relates to the six-month period ending on June 30, 2025, with key dates including an ex-date of September 2, 2025, a record date of September 3, 2025, and a payment date of September 18, 2025. This announcement reflects Sigma’s ongoing commitment to returning value to its shareholders and may impact its financial positioning and investor relations positively.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd announced key changes in its executive management team, highlighting a strategic focus on talent development and succession planning. Mark Davis will step down as Group CFO, and Damien Gance will transition from executive duties to a non-executive director role. Mark Conway is appointed Chief Strategy and Business Development Officer, while Mario Tascone becomes Deputy CEO of Retail. These changes are aimed at supporting Sigma’s growth and integration efforts post-merger, reflecting the company’s commitment to strengthening its management team and executing long-term growth plans.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Limited reported a 41% increase in EBIT following its merger with Chemist Warehouse Group, highlighting strong growth and expanded market reach. The company upgraded its synergy target to $100 million annually within four years, reflecting operational efficiencies and cost reductions. The retail network’s performance was robust, with significant sales growth in key product categories. Sigma plans to close its physical stores in China, focusing on online sales, and optimize its distribution network by closing certain centers in Australia, aiming for improved service delivery and cost efficiency.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has announced the release of 558,119,895 fully paid ordinary shares from voluntary escrow, effective after the close of trading on the ASX on August 27, 2025. This move is part of the company’s strategic financial management, with the remaining escrowed shares set to be released by August 2026 or upon the announcement of financial results for the period ending June 2026, potentially impacting the company’s stock liquidity and shareholder value.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Limited has announced its 2025 Annual General Meeting (AGM) scheduled for 22 October 2025, to be held in Melbourne as a hybrid meeting. This approach allows shareholders to participate either in person or remotely, reflecting Sigma’s commitment to accessibility and engagement with its stakeholders.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.30 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd has issued a correction to an earlier filed Appendix 3X regarding the shareholding of its director, Jack Gance. An administrative oversight led to the omission of 2,205 ordinary shares directly held by Mr. Gance, which have now been corrected in the records. This adjustment increases his total shareholding to 1,579,052,263 shares. Sigma emphasizes its commitment to compliance with ASX disclosure requirements and assures stakeholders that this was an isolated incident, with no impact on recent voting outcomes at the company’s extraordinary general meeting.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.
Sigma Healthcare Ltd is set to release its FY25 Full Year results on August 27, 2025, following its acquisition of the Chemist Warehouse Group. This acquisition is treated as a reverse acquisition for accounting purposes, impacting the presentation of financial statements. The results will include a full twelve-month contribution from CWG, and Sigma will provide normalised and pro forma financial results to adjust for merger-related costs. This strategic move is expected to enhance Sigma’s market positioning and provide stakeholders with a clearer view of its financial health post-acquisition.
The most recent analyst rating on (AU:SIG) stock is a Buy with a A$3.45 price target. To see the full list of analyst forecasts on Sigma Healthcare Ltd stock, see the AU:SIG Stock Forecast page.